Exemestane in the adjuvant treatment of breast cancer in postmenopausal women

Muaiad Kittaneh, Stefan Glück

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the production of estrogen. The majority of breast cancers are sensitive to the proliferative effects of estrogen. Exemestane is approved for the adjuvant treatment of postmenopausal women with breast cancer after 2 to 3 years of tamoxifen therapy, based on a 32% improvement in disease-free survival compared with 5 years of tamoxifen alone (P <0.001). Exemestane has also shown clinical benefts as an upfront therapy. The safety profle of exemestane shares some side effects with tamoxifen (hot fashes and arthralgia), but is not associated with an increased risk of endometrial cancer or thromboembolic events. This review will discuss in detail the effcacy and safety of exemestane in early breast cancer.

Original languageEnglish (US)
JournalBreast Cancer: Basic and Clinical Research
Issue number1
StatePublished - 2011
Externally publishedYes


  • Aromatase inhibitor
  • Breast cancer
  • Disease-free survival
  • Exemestane
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Exemestane in the adjuvant treatment of breast cancer in postmenopausal women'. Together they form a unique fingerprint.

Cite this